# Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

> **NCT02453009** · PHASE2 · COMPLETED · sponsor: **Santa Chiara Hospital** · enrollment: 246 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Prednisone
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02453009
- **Lead sponsor:** Santa Chiara Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2018-04
- **Final completion:** 2019-04
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02453009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02453009, "Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02453009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*